{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:43:35Z","timestamp":1762325015670,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"13-14","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00508-021-01868-1","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T14:02:57Z","timestamp":1621951377000},"page":"641-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Challenges in hepatitis\u00a0C elimination despite highly effective antiviral agents in patients with and without intravenous drug use"],"prefix":"10.1007","volume":"133","author":[{"given":"Simona","family":"Bota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Razpotnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Hucke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Urak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Flatscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-2728","authenticated-orcid":false,"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"1868_CR1","first-page":"34","volume":"6","author":"WHO","year":"1999","unstructured":"WHO. Global surveillance and control of Hepatitis C. Report of a\u00a0WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J\u00a0Viral Liver. 1999;6:34\u20135.","journal-title":"J Viral Liver"},{"key":"1868_CR2","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed: 12. October 2020."},{"key":"1868_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/liv.13186","volume":"37","author":"A Kandeel","year":"2017","unstructured":"Kandeel\u00a0A, Genedy\u00a0M, El-Refai\u00a0S, et al. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37:45\u201353.","journal-title":"Liver Int"},{"key":"1868_CR4","first-page":"373","volume":"19","author":"L Gheorghe","year":"2010","unstructured":"Gheorghe\u00a0L, Csiki\u00a0IE, Iacob\u00a0S, et\u00a0al. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a\u00a0nationwide survey 2006\u20132008. J\u00a0Gastrointestin Liver Dis. 2010;19:373\u20139.","journal-title":"J Gastrointestin Liver Dis"},{"key":"1868_CR5","unstructured":"https:\/\/cdafound.org\/dashboard\/polaris\/maps_prev.html. Accessed 28 Mar 2020."},{"key":"1868_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"The Polaris Observatory HCV Collaborators","year":"2017","unstructured":"The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a\u00a0modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1868_CR7","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM198911303212204","volume":"321","author":"AM Di Bisceglie","year":"1989","unstructured":"Di Bisceglie\u00a0AM, Martin\u00a0P, Kassianides\u00a0C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N\u00a0Engl J Med. 1989;321:1506\u201310.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"1868_CR8","first-page":"8","volume":"23","author":"L Chemello","year":"1995","unstructured":"Chemello\u00a0L, Cavalletto\u00a0L, Bernardinello\u00a0E, et\u00a0al. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J\u00a0Hepatol. 1995;23(Suppl 2):8\u201312.","journal-title":"J Hepatol"},{"key":"1868_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns\u00a0MP, McHutchison\u00a0JG, Gordon\u00a0SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a\u00a0randomised trial. Lancet. 2001;358:958\u201365.","journal-title":"Lancet"},{"key":"1868_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/hep.25892","volume":"56","author":"P Marcellin","year":"2012","unstructured":"Marcellin\u00a0P, Cheinquer\u00a0H, Curescu\u00a0M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012;56:2039\u201350.","journal-title":"Hepatology"},{"key":"1868_CR11","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal\u00a0N, Reddy\u00a0KR, Nelson\u00a0DR, et\u00a0al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N\u00a0Engl J Med. 2014;370:1483\u2013893.","journal-title":"N Engl J Med"},{"key":"1868_CR12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal\u00a0N, Zeuzem\u00a0S, Kwo\u00a0P, et al. ION\u20111 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N\u00a0Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"1868_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14874","author":"H Toyoda","year":"2019","unstructured":"Toyoda\u00a0H, Atsukawa\u00a0M, Watanabe\u00a0T, et al. Real-world experience of 12-week direct-acting antiviral regimen of\u00a0glecaprevir\u00a0and pibrentasvir in patients with chronic hepatitis C virus infection. J\u00a0Gastroenterol Hepatol. 2019; https:\/\/doi.org\/10.1111\/jgh.14874.","journal-title":"J Gastroenterol Hepatol"},{"key":"1868_CR14","doi-asserted-by":"publisher","first-page":"e0214795","DOI":"10.1371\/journal.pone.0214795","volume":"14","author":"P Buggisch","year":"2019","unstructured":"Buggisch\u00a0P, Wursthorn\u00a0K, Stoehr\u00a0A, et al. Real-world effectiveness and safety of sofosbuvir\/velpatasvir and\u00a0ledipasvir\/sofosbuvir hepatitis C treatment in a\u00a0single centre in Germany. PLoS ONE. 2019;14:e214795.","journal-title":"PLoS ONE"},{"key":"1868_CR15","volume-title":"Global health sector strategy on viral hepatitis, 2016\u20132021","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis, 2016\u20132021. Geneva: World Health Organization; 2016."},{"key":"1868_CR16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","volume":"393","author":"A Heffernan","year":"2019","unstructured":"Heffernan\u00a0A, Cooke\u00a0GS, Nayagam\u00a0S, et\u00a0al. Scaling up prevention and treatment towards the elimination of hepatitis C: a\u00a0global mathematical model. Lancet. 2019;393:1319\u201329.","journal-title":"Lancet"},{"key":"1868_CR17","volume-title":"Eliminating viral hepatitis: the investment case","author":"A Pedrana","year":"2018","unstructured":"Pedrana\u00a0A, Howell\u00a0J, Schr\u00f6der\u00a0S, et\u00a0al. Eliminating viral hepatitis: the investment case. Doha: World Innovation Summit for Health; 2018."},{"key":"1868_CR18","unstructured":"https:\/\/cdafound.org\/dashboard\/polaris\/maps.html#pablo. Accessed 28 Mar 2020."},{"key":"1868_CR19","unstructured":"Burnet Institute. The Prime study: treating hepatitis C in primary healthcare setting. 2018. www.burnet.edu.au. Accessed: 12. October 2020."},{"issue":"Supplement","key":"1868_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0168-8278(17)30406-3","volume":"66","author":"AH Litwin","year":"2017","unstructured":"Litwin\u00a0AH, Agyemang\u00a0L, Akiyama\u00a0M, et\u00a0al. The PREVAIL Study: Intensive models of HCV care for people who inject drugs. J\u00a0Hepatol. 2017;66(Supplement):72.","journal-title":"J Hepatol"},{"key":"1868_CR21","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S0618-8278(19)30452-9","volume":"70","author":"C Schmidbauer","year":"2019","unstructured":"Schmidbauer\u00a0C, Schuetz\u00a0A, Schwanke\u00a0C, et al. Interim results of an ongoing project to eliminate chronic hepatitis C in people who inject drugs with ongoing intravenous drug use and a\u00a0high risk of non-adherence to direct-acting antivirals in Vienna. J\u00a0Hepatol. 2019;70:e239.","journal-title":"J Hepatol"},{"key":"1868_CR22","doi-asserted-by":"publisher","first-page":"ofy120","DOI":"10.1093\/ofid\/ofy120","volume":"5","author":"A Alimohammadi","year":"2018","unstructured":"Alimohammadi\u00a0A, Holeksa\u00a0J, Thiam\u00a0A, et al. Real-world efficacy of direct-acting antiviral therapy for\u00a0HCV infection\u00a0affecting people who inject drugs delivered in a\u00a0multidisciplinary setting. Open Forum Infect Dis. 2018;5:ofy120.","journal-title":"Open Forum Infect Dis"},{"key":"1868_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.025","author":"P Lampertico","year":"2020","unstructured":"Lampertico\u00a0P, Carri\u00f3n\u00a0JA, Curry\u00a0M, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a\u00a0meta-analysis. J\u00a0Hepatol. 2020; https:\/\/doi.org\/10.1016\/j.jhep.2020.01.025.","journal-title":"J Hepatol"},{"key":"1868_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","volume":"69","author":"C Rossi","year":"2018","unstructured":"Rossi\u00a0C, Butt\u00a0ZA, Wong\u00a0S, et al. Hepatitis\u00a0C\u00a0virus reinfection after successful treatment with direct-acting antiviral therapy in a\u00a0large population-based cohort. J\u00a0Hepatol. 2018;69:1007\u201314.","journal-title":"J Hepatol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01868-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-021-01868-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-021-01868-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T10:42:42Z","timestamp":1626777762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-021-01868-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":24,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1007\/s00508-021-01868-1","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Peck-Radosavljevic declares consultation and speaker fees from AbbVie, Gilead, MSD. S.\u00a0Bota: declares speaker fees from AbbVie. F.\u00a0Hucke, C.\u00a0Urak, K.\u00a0Flatscher and M.\u00a0Razpotnik declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of our institution (approval number A38\/18), and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a\u00a0priori approval by the institution\u2019s human research committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}